Oddo BHF Asset Management Sas Buys 1,895 Shares of Eli Lilly and Company $LLY

Oddo BHF Asset Management Sas raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 34,349 shares of the company’s stock after purchasing an additional 1,895 shares during the quarter. Eli Lilly and Company makes up approximately 1.4% of Oddo BHF Asset Management Sas’ portfolio, making the stock its 13th largest holding. Oddo BHF Asset Management Sas’ holdings in Eli Lilly and Company were worth $36,914,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Munro Partners bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $41,397,000. Rakuten Investment Management Inc. grew its holdings in shares of Eli Lilly and Company by 248.2% in the fourth quarter. Rakuten Investment Management Inc. now owns 104,905 shares of the company’s stock worth $113,164,000 after acquiring an additional 74,779 shares during the period. Codex Capital Asset Management L.L.C. grew its holdings in shares of Eli Lilly and Company by 8.1% in the fourth quarter. Codex Capital Asset Management L.L.C. now owns 18,380 shares of the company’s stock worth $19,753,000 after acquiring an additional 1,380 shares during the period. Beacon Financial Advisory LLC grew its holdings in shares of Eli Lilly and Company by 34.8% in the fourth quarter. Beacon Financial Advisory LLC now owns 639 shares of the company’s stock worth $687,000 after acquiring an additional 165 shares during the period. Finally, Abound Financial LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $161,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6%

LLY opened at $1,122.47 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,182.73. The company has a market capitalization of $1.06 trillion, a PE ratio of 39.87, a PEG ratio of 1.23 and a beta of 0.53. The firm’s 50 day simple moving average is $1,006.08 and its two-hundred day simple moving average is $1,016.63.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
• Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
• Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
• Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
• Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
• Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, Daiwa Securities Group increased their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.